Prostate Cancer [2016]: Bulletin #2
Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib] and Clovis Oncology’s rucaparib) that are in Phase III development for men with metastatic castration-resistant prostate cancer (mCRPC). KOLs also provide their first insights on the IMbassador250 Phase III study that was initiated in January 2017 investigating Roche’s anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor Tecentriq (atezolizumab) in combination with Xtandi (enzalutamide) in patients with mCRPC. With Bavarian Nordic’s PROSPECT study due to complete in 2017, KOLs also discuss their expectations for the highly-anticipated study investigating the vaccine PROSTVAC (rilimogene galvacirepvec-rilimogene glafolivec) (PSA-TRICOM) in prostate cancer.
Business Questions:
Business Questions:
- How do KOLs view the biomarker-driven data published for AstraZeneca’s olaparib in prostate cancer?
- What are KOL expectations for olaparib and rucaparib in patients with mCRPC and how do the drugs compare?
- Which treatment settings do KOLs expect PARP inhibitors to gain traction?
- How do the experts view the PD-L1 inhibitor drug class in prostate cancer?
- How does atezolizumab compare with other PD-1/PD-L1 immune checkpoint inhibitors such as Merck & Co.’s Keytruda (pembrolizumab)?
- What are KOL expectations for the Phase III IMbassador250 study with Roche’s atezolizumab?
- Where will immunotherapy combinations be best utilised in patients with prostate cancer?
- What are KOL expectations for Bavarian Nordic’s PROSPECT study with the PROSTVAC vaccine?
- How does PROSTVAC compare to Provenge and what are the key advantages of vaccine treatment?
